Completed PHASE2 INTERVENTIONAL 3-arm NCT03524846

Ascorbic Acid on Restenosis of Dysfunctional Hemodialysis Vascular Access

Effect of Ascorbic Acid Administration on Restenosis of Dysfunctional Hemodialysis Vascular

Sponsor: National Taiwan University Hospital Hsin-Chu Branch

Interventions Ascorbic Acid 300 MG Ascorbic Acid 600 MG Normal saline

Updated 4 times since 2018 Last updated: May 13, 2018 Started: Apr 30, 2011 Primary completion: Oct 31, 2011 Completion: Oct 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03524846, this PHASE2 trial focuses on Hemodialysis Access Failure and remains completed. Sponsored by National Taiwan University Hospital Hsin-Chu Branch, it has been updated 4 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Taiwan University Hospital Hsin-Chu Branch

Data source: National Taiwan University Hospital Hsin-Chu Branch

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.